Immunome IMNM Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -5,947.9%-2,719pp | -3,228.8%-809pp | -2,419.9%-636pp | -1,784.1%+210pp | -1,994.3%+1,388pp | |
| Net margin | -5,593.8%-2,534pp | -3,060%-759pp | -2,301.3%-614pp | -1,687.1%+188pp | -1,875.2%+1,365pp | |
| EBITDA margin | -5,886.7%-2,693pp | -3,193.3%-797pp | -2,396.3%-629pp | -1,767.4%+208pp | -1,975.8%+1,389pp | |
| Free cash flow margin | -5,118.9%-2,229pp | -2,890.1%-908pp | -1,982%-505pp | -1,476.8%— | —— | |
| Returns | ||||||
| Return on equity | -50.1%+1.9pp | -52.1%+40.9pp | -93%-11.8pp | -81.2%-12.0pp | -69.2%+125pp | |
| Return on assets | -46.7%-0.7pp | -46%+34.1pp | -80.1%-8.4pp | -71.7%-9.8pp | -61.9%+88.8pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 21.7×+7.0× | 14.7×+5.8× | 8.9×-3.2× | 12.1×+1.6× | 10.5×+6.4× | |
| Quick ratio | 21.7×+7.0× | 14.7×+5.8× | 8.9×-3.2× | 12.1×+1.6× | 10.5×+6.4× | |
| Cash ratio | 21.3×+6.7× | 14.5×+5.9× | 8.7×+2.4× | 6.3×-2.1× | 8.4×+5.7× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $5.20-28.3% | $7.26+142% | $3.00-3.0% | $3.09-20.0% | $3.87+25.2% | |
| Valuation | ||||||
| Market capitalization | $2.47B+4.4% | $2.37B+133% | $1.02B+31.3% | $776.15M+32.6% | $585.18M-11.7% | |
| Enterprise value | $1.9B+10.2% | $1.72B+129% | $750.67M+18.0% | $636.42M+91.5% | $332.33M-36.6% | |
| Price / sales | 616.2×+275× | 341.4×+236× | 105.3×+43.7× | 61.7×+8.2× | 53.5×-19.8× | |
| Price / book | 4.2×+0.5× | 3.7×-0.1× | 3.9×+1.0× | 2.9×+1.0× | 1.9×-1.8× | |
| EV / sales | 472×+224× | 247.9×+170× | 77.6×+27.0× | 50.6×+20.2× | 30.4×-27.6× | |
| Free cash flow yield | -8.3%+0.2pp | -8.5%+10.4pp | -18.8%+5.1pp | -24%— | —— | |
| Earnings yield | -9.1%-0.1pp | -9%+12.9pp | -21.9%+5.5pp | -27.4%+7.7pp | -35.1%+9.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Immunome's ratios come from?
- Every ratio is computed from Immunome's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.